接受雄激素剥夺治疗后使用225Ac-PSMA-617治疗的mCRPC患者:治疗反应与生存分析
该研究纳入53例雄激素剥夺治疗(ADT)后直接接受225Ac-PSMA-617治疗的转移性去势抵抗性前列腺癌(mCRPC)患者,共给予167个周期。48例(91%)患者PSA下降至少50%,51例(96%)任何程度PSA下降;PSA下降至少50%是多因素分析中无进展生存(PFS)和总生存(OS)的预测因素。PSA下降至少50%组中位PFS为22个月、中位OS尚未达到,PSA下降不足50%组中位PFS为4个月、中位OS为9个月。
要点
- 53例ADT后mCRPC患者接受225Ac-PSMA-617,48例(91%)PSA下降至少50%。
- PSA下降至少50%组中位PFS 22个月 vs 不足50%组4个月;中位OS在至少50%组尚未达到 vs 不足50%组9个月。
- 最常见毒性为1-2级口干(81%),3例出现III-IV级肾毒性,未见严重血液毒性。
核心结论
- 53例mCRPC患者中91%在ADT后立即接受225Ac-PSMA-617治疗出现PSA下降至少50%。
- PSA下降至少50%是预测225Ac-PSMA-617治疗后PFS和OS的最重要单一因素。
- PSA下降至少50%组中位OS在最新随访(55个月)时尚未达到。
- 作者认为这些有利结果提示开展前瞻性随机研究比较225Ac-PSMA-617与当前标准治疗(恩扎卢胺、醋酸阿比特龙、多西他赛)具有重要临床意义。
研究设计与样本
- 研究纳入53例ADT后直接接受225Ac-PSMA-617治疗的mCRPC患者。
- 基线、每周期治疗前及随访时行68Ga-PSMA PET/CT以筛选患者、确定给药活度并评估反应。
- 通过系列PSA测量评估治疗反应。
- 共给予167个周期(中位数3,范围1-7)。
主要发现
- 患者中位年龄63.4岁(范围45-83岁)。
- 48例(91%)患者PSA下降至少50%,51例(96%)患者任何程度PSA下降。
- 30例患者68Ga-PSMA PET转为阴性。
- 多因素分析中PSA下降至少50%预测PFS和OS,血小板计数也预测PFS。
- PSA下降至少50%组估计中位PFS为22个月 vs 不足50%组4个月;不足50%组中位估计OS为9个月,至少50%组在最新随访(55个月)时尚未达到。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
225Ac-PSMA-617, targeting the prostate-specific membrane antigen (PSMA), which is overexpressed on prostate cancer cells, has shown a remarkable therapeutic efficacy in heavily pretreated patients with metastatic castration-resistant prostate carcinoma (mCRPC). Here, we report on treatment outcome and survival using this novel treatment modality in a series of 53 patients with mCRPC directly after their androgen deprivation treatment (ADT). Methods: 225Ac-PSMA-617 was administered to 53 such patients. 68Ga-PSMA PET/CT was obtained at baseline, before every treatment cycle, and on follow-up to select patients for treatment, determine the activity to be administered, and assess their response. Serial prostate-specific antigen (PSA) measurements were obtained for response assessment. Results: The median age of the patients was 63.4 y (range, 45-83 y). In total, 167 cycles were administered (median, 3; range, 1-7). Forty-eight patients (91%) had a PSA decline of at least 50%, and 51 patients (96%) had any decline in PSA. 68Ga-PSMA PET findings became negative in 30 patients. In the multivariate analysis, a PSA decline of at least 50% proved predictive of both progression-free survival (PFS) and overall survival (OS), and platelet count also proved predictive for PFS. The median estimated OS was 9 mo for patients with a PSA decline of less than 50% but was not yet reached at the latest follow-up (55 mo) for patients with a PSA decline of 50% or more. The estimated median PFS was 22 mo for patients with a PSA decline of at least 50% and 4 mo for patients with a PSA decline of less than 50%. No severe hematotoxicity was noted, and only 3 patients had grade III-IV nephrotoxicity. The commonest toxicity seen was grade I-II xerostomia, observed in 81% of patients. Conclusion: In 91% of 53 patients with mCRPC, treatment with 225Ac-PSMA-617 immediately after ADT resulted in at least a 50% decrease in PSA level. Furthermore, a PSA decline of at least 50% proved the single most important factor predicting PFS and OS after 225Ac-PSMA-617 treatment. Of interest, median OS in patients with a PSA decline of at least 50% was not yet reached at the latest follow-up (55 mo). These favorable results suggest that it would be of major clinical relevance to perform a prospective randomized study comparing 225Ac-PSMA-617 with current standard-of-care treatment options such as enzalutamide, abiraterone acetate, and docetaxel after ADT.
引用
- Sathekge M, Bruchertseifer F, Vorster M, et al. mCRPC Patients Receiving 225Ac-PSMA-617 Therapy in the Post-Androgen Deprivation Therapy Setting: Response to Treatment and Survival Analysis. J Nucl Med. 2022. PMID: 35177427. doi:10.2967/jnumed.121.263618
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。